FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

Дата публикации: 29-06-2026 05:06:19

WESTLAKE VILLAGE, Calif., June 29, 2026 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Skyrizi (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease	0	13.95	26-06-2026
2	Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)	0	16.04	06-08-2026
3	FDA Approves Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease	0	18.73	26-06-2026
4	FDA Approves Pluvicto for PSMA+ Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	0	17.15	31-07-2026
5	FDA Approves Pasatru (garetosmab-grts) for the Treatment of Fibrodysplasia Ossificans Progressiva	0	15.91	19-08-2026
6	FDA Grants Accelerated Approval to Tudriqev (vusolimogene oderparepvec-wtpg) in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma	0	15.38	06-08-2026
7	New PILL for psoriasis approved... giving hope to millions suffering from debilitating skin condition	0	5.26	18-03-2026
8	FDA Approves Revtorpyk (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer	0	18.09	14-07-2026
9	Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to Treat Primary Biliary Cholangitis (PBC) Granted Priority Review by the US FDA	0	11.94	28-05-2026
10	Glenmark Receives U.S. FDA Approval to Expand the Use of Ryaltris Nasal Spray for Children Aged 6 to Less Than 12 Years	0	13.57	21-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 19.68. Источник: www.drugs.com.